Atualização no Tratamento da Hipertensão Arterial Pulmonar

Fernandes, Constantino José; Calderaro, Daniela; Assad, Ana Paula Luppino; Salibe-Filho, William; Kato-Morinaga, Luciana Tamie; Hoette, Susana; Piloto, Bruna; Castro, Marcela Araújo; Lisboa, Roberta Pontes; Silva, Taysa Antonia Felix da; Martins, Murillo de Araújo; Alves-Jr, Jose Leonidas; Jardim, Carlos; Terra-Filho, Mário; Souza, Rogério

doi:10.36660/abc.20200702

Cited by 12 publications

(2 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Population studies have shown that the average mPAP in healthy individuals is about 14 mmHg and rarely exceeds 19 mmHg [10]. Elevated pulmonary pressure, up to 19-25 mmHg, increases mortality and the further risk of developing full-blown PH [11][12][13][14][15]. The search for a borderline between "normal" and elevated pressure in pulmonary circulation led, in 2018 [14], to a proposal for a new frontier of the PH of mPAP ≥ 20 mmHg (i.e., two standard deviations above mean pressure) obtained with right heart catheterization.…”

Section: Pulmonary Hypertensionmentioning

confidence: 99%

Why Multitarget Vasodilatory (Endo)cannabinoids Are Not Effective as Antihypertensive Compounds after Chronic Administration: Comparison of Their Effects on Systemic and Pulmonary Hypertension

Remiszewski

Malinowska

2022

Pharmaceuticals

View full text Add to dashboard Cite

Systemic and pulmonary hypertension are multifactorial, high-pressure diseases. The first one is a civilizational condition, and the second one is characterized by a very high mortality rate. Searching for new therapeutic strategies is still an important task. (Endo)cannabinoids, known for their strong vasodilatory properties, have been proposed as possible drugs for different types of hypertension. Unfortunately, our review, in which we summarized all publications found in the PubMed database regarding chronic administration of (endo)cannabinoids in experimental models of systemic and pulmonary hypertension, does not confirm any encouraging suggestions, being based mainly on in vitro and acute in vivo experiments. We considered vasodilator or blood pressure (BP) responses and cardioprotective, anti-oxidative, and the anti-inflammatory effects of particular compounds and their influence on the endocannabinoid system. We found that multitarget (endo)cannabinoids failed to modify higher BP in systemic hypertension since they induced responses leading to decreased and increased BP. In contrast, multitarget cannabidiol and monotarget ligands effectively treated pulmonary and systemic hypertension, respectively. To summarize, based on the available literature, only (endo)cannabinoids with a defined site of action are recommended as potential antihypertensive compounds in systemic hypertension, whereas both mono- and multitarget compounds may be effective in pulmonary hypertension.

show abstract

Section: Pulmonary Hypertensionmentioning

confidence: 99%

Why Multitarget Vasodilatory (Endo)cannabinoids Are Not Effective as Antihypertensive Compounds after Chronic Administration: Comparison of Their Effects on Systemic and Pulmonary Hypertension

Remiszewski

Malinowska

2022

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Among the 5 clinical subgroups of PH, the most common is idiopathic pulmonary arterial hypertension (PAH), associated with increased morbidity and mortality rate. 1 Exercise capacity, WHO functional class, hemodynamic values, findings on imaging, and biomarkers of myocardial dysfunction are parameters used to predict the survival of patients with PH. 2 This is a great clinical challenge; the improvement of patients' quality of life and the variability between therapies worsens because a proper care provider decision is expected since it might affect the outcome.…”

mentioning

confidence: 99%